Navigation Links
New Diabetes Research To Be Presented at FOCIS Annual Meeting
Date:6/4/2008

Federation of Clinical Immunology Societies presentations highlight important findings recognized by Juvenile Diabetes Research Foundation awards

BOSTON, June 4 /PRNewswire-USNewswire/ -- The Federation of Clinical Immunology Societies (FOCIS) announces the presentation of awards to two researchers recognizing significant findings related to advancement of Type 1 Diabetes research. The awards will be made following a research symposia on June 5, in conjunction with the 8th annual meeting of the Federation of Clinical Immunology Societies (FOCIS), being held at the Boston Marriott Copley Place, June 5-9. During the FOCIS annual meeting, an international representation of leading scientists will discuss recent advances in the understanding and treating of immune-mediated diseases in a series of 55 educational sessions presented to 1,200 researchers and physicians at FOCIS 2008. The Juvenile Diabetes Research Foundation (JDRF), in conjunction with FOCIS, is the sponsor of the special awards in the area of type 1 diabetes research.

Anti-CD20 therapy delays or prevents recurrent type 1 diabetes

This study, led by Changyun Hu, Yale University School of Medicine, New Haven, CT, shows that therapy with a monoclonal antibody to a marker on B lymphocytes leads to effective therapy of type 1 diabetes in a preclinical model. Similar therapies are known to be effective for some forms of cancer and other autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, and a current clinical trial sponsored by the National Institutes of Health is evaluating the comparable treatment in young adults newly diagnosed with autoimmune diabetes. Type 1 diabetes is an autoimmune disease where white cells of the immune system attack the insulin-producing beta cells. Current therapy with insulin does not address the underlying cause. The Yale group studied the mechanisms by which anti-CD20 therapy works in diabetes treatment, which has the potential for short-term therapy to lead to long-term benefits--even potential reversal of disease. Other investigators contributing to the new findings are from the University of Bristol, Bristol, United Kingdom.

Glucose levels can accelerate damage to insulin-producing cells

This study, led by Anna Skowera, King's College London, School of Medicine at Guy's, London, United Kingdom earned the second of the special research awards. Dr. Skowera's research identified a type of killer T lymphocyte which responds to a target comprised on a sequence within the precursor of insulin (called preproinsulin). They found that the target sequence is displayed at higher and higher levels by the insulin-producing beta cell as the glucose concentration around it goes up. In other words, the beta cell contributes to its own destruction when it tries to respond to high glucose levels by making more of this target sequence. The findings bring researchers closer to finding the elements causing of beta cell destruction and to strategies for the prevention of this destruction. One important implication of this study is that maintaining good glucose blood levels is very important for regulating the amount of beta cell damage. Other investigators contributing to the new findings include Min Zhao, Guo Cai Huang and Mark Peakman, also of King's College, London.

About Diabetes, JDRF, and FOCIS

Diabetes is the leading cause of kidney failure and adult blindness in the United States, and is the sixth leading cause of death, shortening life expectancy by an average of 7 to 10 years. Approximately 21 million Americans have diabetes, including 3 million with type 1 diabetes.

The JDRF is the leading charitable funder and advocate of type 1 (juvenile diabetes research worldwide. The mission of JDRF is to find a cure for diabetes and its complications through support of research.

FOCIS is a federation made up of 36 professional societies dedicated to improving human health through immunology. The FOCIS annual scientific meeting hosts delegates representing diverse specialties related to clinical immunology including allergy, dermatology, diabetes, genetics, multiple sclerosis, nephrology, oncology, pathology, transplantation and more. This four and one-half day symposium is an energetic working forum for the exchange of cutting-edge science and insights into autoimmune and inflammatory diseases.

For more information about FOCIS 2008 visit http://www.focisnet.org.

Contact: Gail Bast

FOCIS Executive Director

Email: gbast@focisnet.org

Cell: (414) 640-1635


'/>"/>
SOURCE Federation of Clinical Immunology
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Novo Nordisk Changing Diabetes(R) Bus Boogies into San Francisco on World Tour to Beat Diabetes
2. Long-term pesticide exposure may increase risk of diabetes
3. Discovery of new signal pathway important to diabetes research
4. Insulet Announces Development Agreement for the First Non-Diabetes Drug Delivery Application for the OmniPod System
5. American Diabetes Association Receives $450,000 Grant From Abbott Fund for Latino Community Initiatives
6. Medifast, Inc. to Present at the Canaccord Adams Diabetes & Obesity Conference
7. Metformin increases pathologic complete response rates in breast cancer patients with diabetes
8. International Diabetes Federation Commits to Improving Diabetes Education Globally Through Centres of Education
9. Panel Calls for Better Diabetes Screening
10. International Diabetes Federation grant supports study to prevent type 2 diabetes in India
11. Insulet Corporation to Present at the Canaccord Adams Diabetes & Obesity Conference on June 6, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... August 16, 2017 , ... LabRoots , the leading provider ... the world, is excited to announce Andrew Ly as the winner of the LabRoots ... textbook costs. , Ly, who is in his third year at the University ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... Fusion Flix ... premium original programming over four countries and millions of viewers in a partnership with ... rent or buy On-Demand and fully available on Blu Ray disc in 2018. Proceeds ...
(Date:8/16/2017)... ... 2017 , ... Kaviva , a health engagement technology ... market, with Los Angeles-based AIDS Healthcare Foundation ( AHF ), to provide their ... for nearly 800,000 individuals worldwide and is the largest HIV/AIDS organization in the ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... and marketers of high-quality anti-aging skincare solutions, recently announced the launch of two ... are an affordable, yet effective alternative to expensive plastic surgery or in-patient cosmetic ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... “Mom, God's Got This: Jamie's Story” is ... in love with the Lord and has an insatiable appetite for God’s Word. , “I ... those shelves, free gifts retrieved from packages of oatmeal. I have one to this day ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... announced today that its fully owned USA -operating ... City Office in Yonkers, New York to ... 2 ) homecare therapy. This new East Coast location has also ... the company,s DMEPOS accreditation for Home/Durable Medical Equipment Services. ... Advanced Oxygen Therapy Inc. New York ...
(Date:8/11/2017)... , Aug. 11, 2017 DarioHealth Corp. (NASDAQ: ... health and big data solutions, today announced that it ... August 14 and host a conference call at 9:00am ... operating and financial results and its strategy and outlook ... hosted by Erez Raphael , Chief Executive Officer, ...
(Date:8/8/2017)... Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a ... reports its financial results for the second quarter ended ... the second quarter 2017 and to date: ... development programs for the Company,s lead project, BL-8040: ... study with BL-8040 as novel stem cell mobilization treatment ...
Breaking Medicine Technology: